Jeil Pharma Holdings Statistics
Total Valuation
Jeil Pharma Holdings has a market cap or net worth of KRW 126.34 billion. The enterprise value is 337.02 billion.
Market Cap | 126.34B |
Enterprise Value | 337.02B |
Important Dates
The last earnings date was Monday, November 11, 2024.
Earnings Date | Nov 11, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Jeil Pharma Holdings has 15.35 million shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 15.35M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | n/a |
Owned by Insiders (%) | 76.13% |
Owned by Institutions (%) | 0.02% |
Float | 2.17M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.16 |
PB Ratio | 0.38 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 117.55, with an EV/FCF ratio of -56.43.
EV / Earnings | -8.52 |
EV / Sales | 0.43 |
EV / EBITDA | 117.55 |
EV / EBIT | n/a |
EV / FCF | -56.43 |
Financial Position
The company has a current ratio of 1.03, with a Debt / Equity ratio of 0.35.
Current Ratio | 1.03 |
Quick Ratio | 0.66 |
Debt / Equity | 0.35 |
Debt / EBITDA | 52.71 |
Debt / FCF | -25.30 |
Interest Coverage | -1.01 |
Financial Efficiency
Return on equity (ROE) is -13.51% and return on invested capital (ROIC) is -1.09%.
Return on Equity (ROE) | -13.51% |
Return on Assets (ROA) | -0.73% |
Return on Capital (ROIC) | -1.09% |
Revenue Per Employee | 20.09B |
Profits Per Employee | -1.01B |
Employee Count | 39 |
Asset Turnover | 0.88 |
Inventory Turnover | 4.34 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.62% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -17.62% |
50-Day Moving Average | 8,718.20 |
200-Day Moving Average | 9,841.00 |
Relative Strength Index (RSI) | 34.90 |
Average Volume (20 Days) | 6,092 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Jeil Pharma Holdings had revenue of KRW 783.56 billion and -39.54 billion in losses. Loss per share was -2,575.85.
Revenue | 783.56B |
Gross Profit | 206.27B |
Operating Income | -10.47B |
Pretax Income | -55.62B |
Net Income | -39.54B |
EBITDA | 2.87B |
EBIT | -10.47B |
Loss Per Share | -2,575.85 |
Balance Sheet
The company has 48.04 billion in cash and 151.11 billion in debt, giving a net cash position of -103.07 billion or -6,714.04 per share.
Cash & Cash Equivalents | 48.04B |
Total Debt | 151.11B |
Net Cash | -103.07B |
Net Cash Per Share | -6,714.04 |
Equity (Book Value) | 436.29B |
Book Value Per Share | 21,410.33 |
Working Capital | 10.95B |
Cash Flow
In the last 12 months, operating cash flow was -1.49 billion and capital expenditures -4.48 billion, giving a free cash flow of -5.97 billion.
Operating Cash Flow | -1.49B |
Capital Expenditures | -4.48B |
Free Cash Flow | -5.97B |
FCF Per Share | -389.06 |
Margins
Gross margin is 26.33%, with operating and profit margins of -1.34% and -5.05%.
Gross Margin | 26.33% |
Operating Margin | -1.34% |
Pretax Margin | -7.10% |
Profit Margin | -5.05% |
EBITDA Margin | 0.37% |
EBIT Margin | -1.34% |
FCF Margin | -0.76% |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.61%.
Dividend Per Share | 50.00 |
Dividend Yield | 0.61% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | 0.61% |
Earnings Yield | -31.30% |
FCF Yield | -4.73% |
Stock Splits
The last stock split was on April 17, 2006. It was a forward split with a ratio of 10.
Last Split Date | Apr 17, 2006 |
Split Type | Forward |
Split Ratio | 10 |
Scores
Jeil Pharma Holdings has an Altman Z-Score of 1.2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.2 |
Piotroski F-Score | n/a |